No Data
No Data
Can Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Lilly to Participate in TD Cowen's 45th Annual Health Care Conference
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $900
Eli Lilly & Co: Promising Growth Driven by Innovative Pipeline and Market-Leading Weight-Loss Treatments
Oh its going : Nothing.
Madhusudhan Talluri : not finding any news.... the way it dropped all thru day it looks like an algo selling - someone big probably unloading after recent spike.
Junius Falcon : It is normal to retrace to a previous jump gap to provide market liquidity.
Technically, it hit a resistance level and it retraces